Bosh sahifaGRF • BME
add
Grifols SA Class A
Yopilish kursi
9,38 €
Kunlik diapazon
9,21 € - 9,44 €
Yillik diapazon
7,03 € - 11,35 €
Bozor kapitalizatsiyasi
5,84 mlrd EUR
Oʻrtacha hajm
1,50 mln
Narx/foyda
40,02
Dividend daromadliligi
-
Asosiy maydon
BME
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(EUR) | dek, 2024info | Y/Y qiyosi |
---|---|---|
Daromad | 1,98 mlrd | 11,66% |
Joriy xarajat | 353,12 mln | 20,32% |
Sof foyda | 68,97 mln | 76,86% |
Sof foyda marjasi | 3,49 | 58,64% |
Har bir ulushga tushum | — | — |
EBITDA | 495,68 mln | -11,49% |
Amaldagi soliq stavkasi | 60,20% | — |
Balans
Jami aktivlari
Jami passivlari
(EUR) | dek, 2024info | Y/Y qiyosi |
---|---|---|
Naqd pul va qisqa investitsiyalar | 1,00 mlrd | 55,40% |
Jami aktivlari | 21,41 mlrd | 1,97% |
Jami passivlari | 12,80 mlrd | -5,05% |
Umumiy kapital | 8,61 mlrd | — |
Tarqatilgan aksiyalar | 680,41 mln | — |
Narxi/balansdagi bahosi | 1,08 | — |
Aktivlardan daromad | 5,08% | — |
Kapitaldan daromad | 5,79% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
(EUR) | dek, 2024info | Y/Y qiyosi |
---|---|---|
Sof foyda | 68,97 mln | 76,86% |
Operatsiyalardan naqd pul | 514,62 mln | 208,54% |
Sarmoyadan naqd pul | -178,31 mln | -28,31% |
Moliyadan naqd pul | -27,16 mln | -185,08% |
Naqd pulning sof oʻzgarishi | 334,84 mln | 658,87% |
Boʻsh pul | 162,44 mln | 123,56% |
Haqida
Grifols, S.A. is a global healthcare company and manufacturer of plasma-derived medicines founded in Barcelona, Spain, in 1909. With a workforce of over 23,000employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over than 30.
Principally a producer of blood plasma–based products, a field in which it is the European leader and third largest worldwide, and other biopharmaceutical solutions, the company is also a leader in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, in addition to clinical diagnostic technologies. Its portfolio of solutions is designed to enhance safety from donation to transfusion. Grifols also provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. Additionally, the company supply tools, information and services that enable hospitals, pharmacies and healthcare professionals to deliver expert medical care. Wikipedia
CEO
Tashkil etilgan
18-noy, 1940
Sayt
Xodimlar soni
23 833